ALBANY, New York, 19 mars 2026 (GLOBE NEWSWIRE) -- Curia, acteur majeur de la recherche, du développement et de la fabrication sous contrat (CDMO), annonce ce jour la progression de l’extension de son site de production [...] Read more »
Curia erweitert seine Produktionskapazitäten in Glasgow und verbessert seine Plattform zur Entwicklung von Zelllinien
ALBANY, New York, March 19, 2026 (GLOBE NEWSWIRE) -- Curia, ein führendes Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CDMO), gab heute Fortschritte bei der Erweiterung seiner Anlage für sterile Arzneimittel in [...] Read more »
Curia Expande Capacidade de Fabricação de Glasgow e Aprimora Plataforma de Desenvolvimento de Linhagem Celular
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato (CDMO), anunciou hoje o progresso na expansão da sua unidade [...] Read more »
Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility [...] Read more »
Kyowa Kirin Recupera Controle do Programa de Desenvolvimento e Comercialização do Rocatinlimab, Demonstrando Forte Compromisso para Abordar a Alta Necessidade Médica Não Atendida na Dermatite Atópica
- A Kyowa Kirin afirma o compromisso de desenvolver o rocatinlimab como um ativo diferenciado de mudança de vida com potencial de mercado significativo.
- Read more »
Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
- Kyowa Kirin réaffirme sa volonté de développer le rocatinlimab comme un traitement innovant capable d’améliorer significativement la vie des patients, tout en [...] Read more »
Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis
- Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.
- Read more »
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
- Kyowa Kirin affirms commitment to developing rocatinlimab as a life–changing differentiated asset with significant market potential.
- Rocatinlimab’s novel approach as an investigational [...] Read more »
Countdown for a Cure Partners with Dr. Taz Bhatia M.D. and hol+ to Advance Mitochondrial Research and Awareness
ATLANTA, Jan. 23, 2026 (GLOBE NEWSWIRE) — Dr. Taz Bhatia M.D., a nationally recognized integrative medicine physician, author, and founder of hol+, has partnered with nonprofit Countdown for a Cure (CFAC) to help advance [...] Read more »
Attindas Hygiene Partners Amplia Parceira na Europa com Importante Aquisição
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners dá um passo importante para sua estratégia de crescimento hoje com a aquisição da Societá Italiana [...] Read more »